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1 INTRODUCTION 
 
1.1 Colorectal cancer 
 
 
Colorectal cancer is the third most common cancer worldwide 
and the second leading cause of cancer-related death in the 
Western world. Approximately 75% of patients with colorectal 
cancer present with localised disease, whereas metastatic disease 
accounts for 25% of newly diagnosed patients. Systemic 
treatment is based on cytotoxic agents and monoclonal antibodies 
targeting epidermal growth factor receptor (EGFR) and vascular 
endothelial growth factor (VEGF). In the last decade, the optimal 
use of these agents in patients with metastatic disease has 
dramatically improved median survival from 6 to 24 months. 
However, despite all these therapeutic advances, the prognosis of 
patients with metastatic colorectal cancer remains poor, and, apart 
from those having surgery of isolated metastases, long-term 
survival is very low.  
In the adjuvant setting, 5-fluorouracil- and oxaliplatin based 
chemotherapy has demonstrated a significant improvement in 
disease-free and overall survival, particularly in patients with 
resected stage III disease. The quantitative benefit of adjuvant 
therapy in patients with stage II colorectal cancer is less 
 8
important and remains a matter of controversy. However, despite 
this strategy, almost 40% of patients diagnosed initially with 
localised disease will develop recurrences. Therefore, there is a 
need to better identify these patients at risk and to adapt to them 
what we could consider optimal treatment. Anatomic criteria 
defined by Dukes almost 80 years ago are currently the basis of 
the tumour/node/metastasis (TNM) staging system upon which 
most clinical decisions concerning postoperative treatment are 
based. 
However, some changes are expected to occur in the molecular 
medicine era. A high number of articles are reporting on the 
importance of several molecular markers, either predictive or 
prognostic, to help clinicians make better decisions with cancer 
patients. In light of this challenge, researchers are attempting to 
determine a more rational and pathogenic approach to cancer 
therapy. Markman et al. provide a well-written and 
comprehensive review aiming to highlight the prognostic and 
predictive biomarkers in colorectal cancer. An extensive amount 
of information is being published on many different mechanisms 
that may have therapeutic interest in colorectal cancer, but the 
important point is how to apply them properly in clinical practice. 
Improved understanding of cancer biology and advances in 
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biotechnology bring us closer to the concept of individualised 
treatment. A key component of this new paradigm is development 
of biomarkers that can guide application of new or even existing 
treatments. This requires a deep understanding of the relationship 
between biomarker and treatment effect. 
Some recently published randomised studies are also designed to 
assess the importance of specific biomarkers. In others, the 
authors attempt to justify a retrospective assessment of certain 
biomarkers.  
Nowadays, KRAS status testing is required prior to initiation of 
anti-EGFR antibodies. 
Due to the complexity of the EGFR signalling system, it is likely 
that predictive algorithms will be developed for metastatic 
colorectal cancer, thus adding other molecular biomarkers. For 
instance, combining KRAS mutational status with the presence of 
b-Raf proto-oncogene serine/ threonine-protein kinase (BRAF) 
and/or phosphoinositide- 3-kinase, catalytic, alpha polypeptide 
(PIK3CA) mutations and phosphatase and tensin homolog 
(PTEN) loss of function might identify additional patients who 
are unlikely to respond to treatment with EGFR-targeted 
monoclonal antibodies.  
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However, these additional markers require further validation 
before they can be incorporated into clinical practice. 
Further work is also required to explore potential early markers of 
response that can be incorporated into the design of future 
prospective clinical trials and guide therapeutic decisions 
regarding continuation of treatment in individual patients. In 
1990, Fearon and Vogelstein presented their well-known model 
for the genetic basis of colorectal neoplasia. They proposed that 
“identification of the genetic alterations present in tumours may 
provide a molecular tool for improved estimation of prognosis in 
patients with colorectal cancer”  
Nowadays, almost two decades later, we still have much to learn 
about the prognostic or predictive value of these and others 
“colorectal cancer biomarkers”. 
Molecular profiling of tumours may certainly let us identify 
patients who are more likely to benefit from a specific therapy. 
This would stimulate clinicians to tailor treatment according to an   
individual patient and/or tumour profile, converting the so-called 
personalised or tailored therapy into a reality. New 
methodologies such as microarray-based gene expression 
profiling, proteomic profiling, comparative genomic 
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hybridisation analysis and metabolomics would allow tumour 
samples to be profiled on a global scale.  
The most frequently used genomewide approach is DNA 
microarray profiling. One platform is the Oncotype DX colon 
cancer test being used to profile gene expression. Molecular 
alterations are used to redesign the taxonomy of solid tumours by 
moving it from a histologically to a genetically based level. 
Parallel development of predictive molecular and clinical markers 
is paramount to achieve the best outcomes from targeted 
treatments, and KRAS is so far the only validated predictive 
molecular marker in colorectal cancer for EGFR-directed 
monoclonal antibodies. In the future, we expect to employ a 
personalised or tailored therapy that will become a reality, with 
less toxicity and superior efficacy. 
This will become a reality only if we are able to improve our 
molecular knowledge, we can consistently validate these new 
biomarkers and we can eventually apply them in our clinical 
decisions. 
Clinical and translational research that is in progress will 
hopefully help to provide the much promised hope of 
personalised medicine in the management of colorectal cancer. 
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We can foresee that in some years, the treatment for advanced 
colon cancer will be based upon molecular features. 
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1. 2 MicroRNAs 
MicroRNAs (miRNAs) are small regulatory RNA molecules 
functioning to modulate gene expression at the post-
transcriptional level, and playing an important role in the control 
of many biological processes, such as cellular development, 
differentiation, proliferation, apoptosis and metabolism. They are 
implicated in pathogenesis, diagnosis and therapeutic aspects of 
viral infections, cardiovascular disease, and neurological and 
muscular disorders. Data recently published suggest that the 
expression of certain genes can be more dependent on the levels 
of regulatory miRNAs than on the levels of messenger RNAs that 
encode the proteins. RNA mediated gene silencing pathways have 
essential roles in development, cell differentiation, cell 
proliferation, cell death, chromosome structure and virus 
resistance. Moreover, studies from the last three years have 
demonstrated that there is altered expression of miRNA genes in 
many human malignancies. 
The DNA sequence that codes for a miRNA gene is longer than 
the miRNA. This DNA sequence includes the miRNA sequence 
and an approximate reverse complement. When this DNA 
sequence is transcribed into a single-stranded RNA molecule, the 
miRNA sequence and its reverse-complement base pair to form a 
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double stranded RNA hairpin loop; this forms a primary miRNA 
structure (pri-miRNA) that contains a stem-loop structure of 
about 80 bases. 
Pri-miRNAs are processed in the nucleus by the RNase III 
enzyme Drosha and DGCR8/Pasha, which excises the stem-loop 
to form the pre-miRNA. Pre-miRNAs are exported from the 
nucleus by Exportin-5, a carrier protein. In the cytoplasm another 
RNase III enzyme, Dicer, cuts the pre-miRNA to generate the 
mature microRNA as part of a short RNA duplex. The RNA is 
subsequently unwound by a helicase activity and incorporated 
into a RNA induced silencing complex (RISC). 
The function of miRNAs appears to be in gene regulation. For 
that purpose, a miRNA is complementary to a part of one or more 
messenger RNAs (mRNAs), usually to a site in the 3' UTR. The 
annealing of the miRNA to the mRNA then inhibits protein 
translation, but sometimes facilitates cleavage of the mRNA. In 
such cases, the formation of the double-stranded RNA through 
the binding of the miRNA triggers the degradation of the mRNA 
transcript through a process similar to RNA interference (RNAi), 
though in other cases it is believed that the miRNA complex 
blocks the protein translation machinery or otherwise prevents 
protein translation without causing the mRNA to be degraded. 
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miRNAs may also target methylation of genomic sites which 
correspond to targeted mRNAs. 
 Ten thousand miRNAs have been discovered in various organisms. 
Generally, each miRNA is thought to regulate multiple genes, 
hundreds of miRNA genes are predicted and several hundreds 
have been already cloned and sequenced from C.elegans, 
Drosophila, Arabidopsis, mice and human. The large number of 
miRNAs and homologous sequences of many miRNAs among 
organisms suggest that these RNAs might constitute an abundant 
and conserved component of the gene regulatory machinery. 
There are three groups of miRNA genes according to their 
genomic location: 
1. Intronic miRNA in protein coding transcription units 
2. Intronic miRNA in noncoding transcription units 
3. Exonic miRNA in noncoding transcription units 
It was initially thought that most miRNA genes are located in 
intergenic regions. A recent analysis of miRNA gene locations 
and transcription units witch involved combining genome 
assemblies and expressed sequence tag databases demonstrated 
more than 70% of mammalian miRNA genes are located in 
defined transcription units. Moreover, two thirds of  miRNA 
genes are found in the introns in the sense orientation. 
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Interestingly miRNAs can be also present in either an exon or an 
intron depending on the alternative splicing pattern.  
Human miRNA genes are located in all chromosomes except Y 
chromosome and they are nonrandomly distributed in the human 
genome. Approximately 50% of known human miRNAs are 
found in clusters and they are transcribed as polycistronic primary 
transcripts. There are usually two or three genes per cluster and 
the largest cluster at 13q31 is composed of seven genes. A cluster 
can contain miRNAs related to each other, suggesting that it is a 
result of gene duplication, or contains unrelated miRNAs. Such 
clustered miRNAs can be functionally related by targeting the 
same gene or different genes in the same metabolic pathway. It is 
possible that even in cases where clustered genes have no 
sequence homology, they may share functional relationships.  
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1.3 MicroRNAs and cancer 
Many studies showed that miRNAs are aberrantly expressed in 
cancer, suggesting their role as a novel class of oncogenes or 
tumor suppressor genes. The findings that miRNAs have a role in 
cancer are supported by the fact that about 50% of miRNA genes 
are localised in cancer-associated genomic regions or in fragile 
sites. Regulation mediated by these genes has possibly a large 
impact on gene expression because, according to computional 
predictions, a single miRNA can target many genes. Many 
authors have reported that each cancer tissue has a specific 
microRNA “signature” and microRNA based cancer 
classification is a very effective and potential tool. First evidence 
of involvement of miRNAs in cancer came from molecular 
studies characterizing the 13q14 deletion in human chronic 
lymphocytic leukemia (CLL). Deletion of the 13q14 region 
occurs in more than half cases of  B cell chronic lymphocytic 
leukemias  and also in 50% of mantle cell lymphomas, in 16–
40% of multiple myelomas and in 60% of prostate cancers, 
suggesting that tumor suppressor(s) gene(s) at 13q14 are involved 
in the pathogenesis of these tumors. Calin et al. (2002) have 
shown that two miRNA genes are located at 13q14.3 within a 30-
kb region of minimal loss in CLL between two exons of the 
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LEU2 gene. Both of these genes, miR-15a and miR-16-1, are 
down-regulated in more than 60% of CLL cases (detected using 
Northern blot analyses). A very similar cluster (miR-15b, miR-
16-2), but with a different promoter, was found on chromosome 
3q25–26.1. It seems that these miRNAs are less intensivelly 
expressed in normal cells but may play a role in the cases of 
13q14 deletions. Putative target of miR-16 is the arginyl-tRNA 
synthetase gene (RARS) because it has a homology of 85% on 
the 20-nt overlap and the levels of expression of the RARS gene 
correlate with the levels of expression of miR-16. Another 
evidence about the target gene for miR-16 came during the 
studies of pituitary adenomas, where miR-15a and miR-16-1 are 
expressed at lower levels as compared to normal pituitary tissue 
and their expression inversely correlates with RARS expression. 
Cimmino et al. (2005) have demonstrated a different possible 
target for miR-15a and miR-16-1, whose expression is inversely 
correlated to BCL2 expression in CLL and they have uncovered 
that both miRNAs negatively regulate BCL2 at a post-
transcriptional level. Moreover, in a leukemic cell line model 
BCL2 repression by these microRNAs induces apoptosis. 
Deregulation of antiapoptotic BCL2 in CLL cells seems to be a 
key event in cancerogenesis. Recently, it became possible to 
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analyze the entire miRNome by microarrays containing all known 
human miRNAs. The use of miRNA microarrays made possible 
to confirm miR-16 deregulation in human CLL and also 
recognize miRNA expression signatures associated with defined 
clinicopathologic features. miR-16-1 and miR-15a , which were 
previously reported to be down-regulated in the majority (68%) 
of CLL cases by Northern analysis,  were found to be expressed 
at low levels in 45% (miR-16-1) and in 25% (miR-15a) of CLL 
samples. These findings, that down-regulation of miR-16-1 and 
miR-15a expression correlates with allelic loss at 13q14, can be 
important for clinical classification of CLL. Patients with a 
normal karyotype or deletion of 13q14 as the sole genetic 
abnormality have a better prognosis than those with a complex 
karyotype or frequent deletion of 11q23 or 17p13. Expression 
profiling of miRNAs in human B-CLL identified significant 
differences in miRNome expression between CLL samples and 
normal CD5+ B lymphocytes. At the top of list of differently 
expressed miRNAs are several miRNAs located exactly inside 
fragile sites. In some miRNA genomic clusters all members are 
aberrantly regulated. In others only some members were 
abnormally expressed such as the largest known miRNA cluster - 
miR-17-92. Two miRNA expression clusters in CLL samples that 
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associate with the presence (20% as a cutoff) or absence of Zap-
70 expression could be identified. ZAP-70 is a tyrosine kinase 
and low level of its expression is a predictor associated with good 
prognosis. Moreover, five differentially expressed miRNAs 
distinguish CLL samples that express unmutated IgVh locus from 
those that express mutated IgVh locus – a favorable prognostic 
factor. A signature composed of 13 microRNAs could well 
discriminate between a group of CLL samples that expresses 
ZAP-70 and unmutated IgVh (patients with worse prognosis) and 
the group that has no expression of ZAP and mutated IgVh 
(patients with better prognosis). Furthermore, members of the 13-
member prognostic signature can well differentiate patients with 
a short interval from diagnosis to initial treatment (treatment 
begins with the development of the symptomatic or progressive 
disease) from patients with a longer interval. To summarize, the 
miRNA expression profile is associated with progression in CLL 
and can serve as a possible prognostic marker. 
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 1.4 miRNAs in Colorectal cancer 
Studies in the field of biomedicine have identified the specific 
miRNAs in colonic tissue and serum that might be used to screen 
for the presence of adenomas and colorectal cancers, and also to 
help predict disease recurrence. Adenomas (polyps) are 
precursors of most colorectal cancers and the progression of these 
lesions to cancer is a multistep process that involves different 
sequential DNA aberrations and changes in gene expression. 
Higher expression levels of miR-21 in adenomas and carcinomas 
relative to normal surrounding colonic tissue suggest that this 
represents an early cellular event in the progression to cancer. 
PTEN is associated with inhibition of cell invasion by blocking 
the expression of extracellular matrix metalloproteases, and miR-
21 promotes cell migration and invasion by targeting the PTEN 
gene. Another pathway of metastasis was recently described for 
colorectal cancers in which miR-21 promotes intravasation, 
invasion and metastasis by downregulating the Pdcd4 gene. 
Overexpressed miRNAs such as miR- 20, miR-21, miR-17-5p, 
miR-15b, miR-181b, miR-191 and miR-200c have been 
implicated in colorectal cancer tissues. These tumour promoter 
miRNAs function by targeting and inhibiting different tumour 
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suppressor genes such as E2F transcription factor 1, tropomyosin 
1, phosphatase and tension homologue gene (PTEN) and 
programmed cell death gene 4 (Pdcd4). Lower levels of mature 
miRNAs such as miR-34a, miR-126, miR- 143, miR-145 and 
miR-342 are also found in colorectal cancers, suggesting that they 
act as tumour suppressor miRNAs. The loss of such miRNAs 
may lead to overactivity of oncogenes. Besides identifying 
different cancer-related miRNAs, scientists are working to 
identify their target genes, messenger RNAs and receptors. Such 
identification will lead to further studies about their role in 
therapeutic manipulation and cancer treatment. For example, the 
putative identified targets of miR-145 are transforming growth 
factor receptor II and insulin receptor substrate 1 (IRS-1). The 
IRS-1 transduces mitogenic, antiapoptotic and anti differentiation 
signal that, in turn, promotes tumour suppressor activity. 
Recent attempts to investigate the role of miRNAs in tumour 
diagnosis have been based on the study of individual targeted 
miRNAs, or the miRNA expression signature, also termed 
miRNA expression profile. Researchers have demonstrated that, 
in addition to the distinction of tumours from normal tissue, 
miRNA expression was characteristic for tumour type, stage and 
other clinically relevant variables. Cummins and co-workers  
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showed overexpression of 18 different miRNAs (tenfold 
overexpression of six miRNAs) and silencing of 32 miRNAs in 
colonic tumour compared with normal colonic tissue. 
In another study, 28 and 64 miRNAs were differentially 
expressed in stage I and II colorectal cancer tissue respectively in 
comparison with paired normal tissue. 
Table 1 summarizes the differential expression of microRNAs in 
colorectal cancer compared with normal flanking tissue identified 
by various studies. The results of these studies suggest that 
variability of individual miRNAs with tumour type and stage 
probably makes the use of a combination of miRNAs a reliable 
method of detecting cancer status. 
Table 1. Differential expression of microRNAs in colorectal 
cancer tissues compared with flanking normal tissue as identified 
in six studies 
 Overexpressed miRNAs                                                Underexpressed miRNAs 
miR-17-5p                                                                                              miR-145  
miR-21 
miR-29b 
miR-30c 
miR-106a 
miR-107 
miR-191 
miR-221 
miR-223 
miR-19a                                                                                                   miR-143  
miR-21                                                                                                     miR-145 
miR-19a                                                                                                   miR-30c 42 
miR-21                                                                                                     miR-133a 
miR-29a                                                                                                   miR-145 
miR-92 
miR-148a 
miR-200b 
miR-15b 24 
miR-181b 
miR-191 
mirR-200c 
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In short, miRNAs more interesting in colorectal cancer are: miR-21, 
miR-31, miR-34, miR-126, miR-135 miR-143, miR-145, miR-200, miR-
342. 
 
• miR-21 is a strong PTEN suppressor. It’s up-regulated in many 
colorectal tumors. It behaves as an oncogene. 
• miR-31 down-regulates FOXC2 and FOXP3 (pro-apoptotic genes) 
and is an oncogene. 
• miR-135 suppresses APC (realising beta-catenina). It was found up-
regolated in vivo in colorectal carcinoma. It behaves as an oncogene 
 • miR-200 targets MLH1 and MSH2 genes and behaves as an 
oncogene. 
• miR-143 suppresses K-Ras and ERK5 sintesis. It was found down-
expressed in colon cancer, in vivo. In vitro, miR143 inhibition upgrades 
cell proliferation, so it  is behaves as a tumor-suppressor. 
• miR-145 targets IRS1 (insulin-receptor-substrate 1), a well-known 
mitogen, and therefore it’s a tumor-suppressor. 
• miR-126 inhibits AKT. It’s down-regolated in many cases of colo-
rectal cancer. It’s a tumor-suppressor. 
• miR-34 targets p53. A possibile mechanism of p53 loss (beyond his 
mutation) is the loss or reduction of miR34 for mutilation of gene in 
CpG islands. (tumor-suppressor). 
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Chapter 2 
 
2.1 Aims of study 
 
The definition of new molecular prognostic and predictive parameters is 
one of the most important aims of clinical research in oncology.  Ideally, 
such parameters could be able to better define the prognosis of a single 
patient and his chance to obtain a clinical response after a specific 
treatment. The objective of this study is to investigate whether the 
expression of several micro RNAs are associated with specific clinical 
outcomes in patients affected by locally advanced rectal cancer treated 
with neoadjuvant chemoradiation and then after with surgery and 
adjuvant chemotherapy, and to identify specific signature associated with  
response to treatment. With the aim to analyze the expression of 
different miRNA in those patients, prior treatment initiation, rectal 
biopsies from primary tumor and from normal mucosa will be done for 
RNA extraction. The Spearman’s correlation test, t-test and logistic 
regression analysis will be used to explore the correlation among these 
biological factors and the pathological response of the tumors, measured 
as tumour regression grade (TRG). Biological factors expression was 
considered as a continuous variable. 
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2.2 Materials and methods  
Patients and treatment 
Forty-6 patients with histological diagnosis of rectal adenocarcinoma 
invading through the intestinal wall or with pelvic lymph node 
involvement as measured by endorectal ultrasonography (uT3/uT4 or 
any uT/N+) was treated with neoadjuvant chemo-radiotherapy. 
Capecitabine was given orally at 825 mg/m2 b.i.d. (two administrations 
each 12 h apart), from day 1 to 14 every 21 days.  
Oxaliplatin was administered i.v. at 50 mg/m2, diluted in 500 ml of 
glucose solution as a 120-min infusion, at days 1 and 8 of each 21-day 
cycle.  
Pelvic conformal RT was delivered at the daily dose of 1.8 Gy, 5 days a 
week, up to 45 Gy in 5 weeks. 
After surgery, further 4 months of adjuvant chemotherapy with CAP or 
weekly 5-FU–leucovorin were proposed to all the patients. The oral 
(CAP) or the i.v. (5-FU–leucovorin) regimen was a patient choice. 
Staging procedures had to be carried out within the 2 weeks preceding 
the treatment start and included blood cell count, biochemistry, blood 
carcinoembryonic antigen level, thorax–abdomen–pelvis CT scan, total 
body positron emission tomography (PET), colonoscopy, and endorectal 
ultrasonography. 
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At 4–6 weeks after chemoradiotherapy completion, the stage of the 
disease was re-evaluated by repeating thorax–abdomen–pelvis CT scan, 
total body PET, and endorectal ultrasonography, in order to assess 
primary tumour response and to exclude the presence of distant 
metastases. 
Patients were monitored weekly by history, physical examination, and 
blood count; complete biochemistry was carried out at each cycle. 
Toxicity was graduated according to National Cancer Institute Common 
Toxicity Criteria, version 3.0. 
The protocol suggested surgery be carried out 6–8 weeks after 
completion of RT, using the total mesorectal excision technique. 
However, the choice of the surgical procedure (i.e. abdominoperineal 
resection or low anterior resection) was at the surgeon’s discretion as it 
was the bridge ileostomy after low anterior resection. 
Specimen dissection and mesorectum evaluation were carried out 
according to the College of American Pathologists protocol for all 
invasive carcinomas of the colon and rectum (revised version of January 
2005; based on AJCC/UICC TNM, 6th edition). Tumour sampling was 
carried out along the neoplasm major axis; mesorectum was always 
inked and sampling was carried out in the points of maximum neoplastic 
infiltration. 
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Pathologic response was independently scored by two pathologists 
(FPDA and MRDA) who did not participate in the clinical data 
gathering, following tumour regression grade (TRG) as described by 
Mandard. (see Table 1). 
Table 1. Tumour regression grade scoring system 
TRG 1:    Complete response with absence of residual 
cancer and fibrosis extending through the wall 
TRG 2:   Presence of residual cancer cells scattered 
through the fibrosis 
TRG 3:    Increase in the number of residual cancer cells, 
with fibrosis predominant 
TRG 4:   Residual cancer outgrowing fibrosis 
 
TRG 5:   Absence of regressive changes 
 
Pathological complete response (TRG1) was observed in 9 patients;  
TRG2 in 19 patients; TRG3 in 12 patients; and TRG4 in 3 patients. 
Overall, nine patients recurred: five with distant metastases, one with 
local recurrence, and three with both local recurrence and distant 
metastases. 
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Tissue processing  
Rectal tumor samples were collected in the operating theater and frozen 
within 15 min in liquid nitrogen after surgery and stored at -80°C. The 
collection and use of tumor samples was approved by the local scientific 
ethical committee and written consent was obtained from the patients. 
 
RNA isolation 
Frozen primary tumor tissues (100 mg) were homogenized at 8000 RPM 
in a Ultraturrax T 10 at 4°C with 1 ml of Trizol until to obtain a totally 
liquid phase and total RNA was extracted and purified using Ambion 
mirVana RNA isolation kit (Applied Biosystems, Italy) according to the 
manufacturer’s instructions. RNA was measured by NanoDrop, ND-
1000 Specthophotometer (NanoDrop Technologies, USA) and quality 
assessed by Agilent Bioanalyzer Assay (Agilent Technologies, 
Germany), which consists of a RNA 6000 Nano Kit, to measure the total 
RNA integrity and concentration, and a Small RNA Kit, to measure the 
small RNA amount and profile. The RNA kits contain chips and reagents 
designed for analysis of total RNA and RNA fragments. Each RNA chip 
contains an interconnected set of microchannels (fig. 1) that is used for 
separation of nucleid acid fragments based on their size as they are 
driven through it electrophoretically. The chips are designed only for use 
with the Agilent 2100 Bioanalyzer (Agilent Technologies, Germany). 
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After their insertion in the Agilent 2100 Bioanalyzer, the chips run and 
the software shows and save their data.  The Agilent 2100 Expert 
Software automatically provides a RNA Integrity Number (RIN). RIN 
provides a quantitative value for RNA integrity that facilities the 
standardization of quality interpretation. Only samples with a RNA 
quality score (RIN) larger than 5 were further processed and aliquots 
were stored at -80°C until use.  
Total RNA characterization provides information on quality of the total 
RNA extracted, which may impact the overall RNA quantification and 
the microarray miRNA profile. The resulting electropherogram typically 
has at least two distinct peaks representing the 18S and 28S ribosomial 
RNA (Fig.2).    
The small RNA assay characterizes the total RNA sample with an 
emphasis on the small RNA content of which of a fraction is miRNA. 
The resulting electropherogram (fig. 3) typically has a number of bands 
or peaks representing small RNAs ranging in size from 10 to 150 nt. The 
miRNA portion is represented by the band or peak ranging from 10 to 40 
nt. These bands or peaks will vary in abundance depending on the total 
miRNA preparation. However, the small RNA assay results may not 
necessarily be an indicator for the miRNA content in the sample, and the 
miRNA microarray assay is a more sensitive technique for detecting  low 
levels of miRNAs.   
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 Fig. 1: Microchannels 
 
 
     18S       28S 
Fig. 2 RNA peaks of a successful sample run 
 
                  miRNA region 
Fig.3 Small RNA Sample Well Results 
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miRNAs Microarray Assay 
miRNA expression was analyzed using Agilent miRNA Microarray 
System with miRNA Complete Labeling and Hybriditazion Kit (Agilent 
Technologies, Germany), which offers all the necessary reagents for 
labelling and hybridization on the miRNA microarray.  
Agilent’s miRNA Complet Labeling and Hyb Kit generates fluorescent 
miRNA with a sample input of 100 ng of total RNA. This method 
involves the dephosphorylation of RNA with Calf Intestinal 
Phosphatase, denaturation by the add of DMSO to total RNA and 
ligation of one Cyanine 3-pCp molecule to the 3’ end of a RNA 
molecule with greater than 90% efficiency. After labelling reaction, the 
samples are assembled with the array slide according to the 
manufacturer’s instructions. The arrays are hybridizied for at least 20 
hours, in a hybridization rotator that rotates at 20 RPM. The day after, 
the microarray slides are washed with Gene Expression Wash Buffers.  
Hybridization signals were detected using the DNA microarray scanner 
G2505B (Agilent Technologies), and all scanned images were analyzed 
using Agilent feature extraction software (v9.5.3.1). Data were analyzed 
using GeneSpring GX 7.3.1 software (Agilent Technologies) and 
normalized as follows: 
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(i) values below 0.01 were set to 0.01. (ii) each measurement was 
divided by the 75th percentile of all measurements to compare one-color 
expression profile. 
 
2.3 Data analysis 
Thirty-nine frozen fresh biopsies of patients affected by a locally 
advanced rectal cancer treated with neoadjuvant chemo-radiotherapy 
have been used for this study. Patients have been divided in three groups 
by TRG: 
Group A: patients with TRG 1 
Group B: patients with TRG 2-4 
Group C: patients not responders 
Each group has been equally divided in two subgroups with regard of 
TRG, with the aim to have a “training set” of 19 patients and a 
“validation set” of 20 patients. 
 A microarray platform has been used to determine miRNA expression. 
Each array is composed by 939 miRNAs, 2689 probes and 15024 spots.   
First of all, Agilent fluorescence of each array has been measured; then 
after, background and negative control (which measures not specific 
fluorescence, for example probe autofluorescence) have been measured 
by total value of fluorescence of each array (fig.4).  
 
 34
                                    Background      Negative control 
Fig.4: Fluorescence Units (FU) (median pixel) 
Reproducibility of fluorescence signals has been tested in replicate spots. 
Co-relation between duplicates and triplicates has been performed, and 
co-relation inter and intra-slides has been performed. So, 796 outliers 
spots (which drift away from media of their probe much more than 2.33 
standard deviation and alone increase media of their probe much more 
than 1.5 times) have been identified and deleted. 
Then, not expressed miRNA have been identified as the negative probes 
in all patients. Thus, 566 of 939 miRNAs (60%) have been identified and 
deleted.  Subsequently, median value of replicated spots of each probe 
(FU media) have been calculated. Not specific levels (negative control) 
have been subtracted from FUmedia value and the logarithm in basis of 
2 has been calculated. Data have been normalized by linear regression.  
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p-value of miRNA has been calculated by probability property for 
independent events. So that, 66 miRNA with p-value < 0.05 have been 
identified (fig. 5). 
 
Fig.5: Selection 1 (66 miRNA) 
SystematicName
pmiRNA A vs 
BC 
FC 
A/BC Cluster Fam Chr 
hsa‐miR‐765 0.000397 2.88 1 mir‐765 1 
hsa‐miR‐1226STAR 0.000418 3.17 1 mir‐1226 3 
hsa‐miR‐1183 0.000747 3.02 1 mir‐1183 7 
hsa‐miR‐1182 0.000801 3.49 1 mir‐1182 1 
hsv1‐miR‐H1 0.000939 3.44 1     
hcmv‐miR‐US4 0.001057 3.14 1     
hsa‐miR‐23aSTAR 0.001852 3.14 1 mir‐23 19 
hsa‐miR‐1274b 0.001952 0.70 0 mir‐1274 19 
hsa‐miR‐483‐5p 0.002028 2.43 1     
hsa‐miR‐622 0.002148 2.97 1 mir‐622 13 
hsa‐miR‐125a‐3p 0.002157 2.36 1     
hsa‐miR‐1224‐5p 0.002649 2.31 1     
hsa‐miR‐188‐5p 0.002955 2.30 1     
hsa‐miR‐424STAR 0.003054 2.47 1 mir‐322 X 
hsa‐miR‐1471 0.003493 3.12 1 mir‐1471 2 
hsa‐miR‐513a‐5p 0.004145 2.64 1     
hsa‐miR‐601 0.004385 2.76 1 mir‐601 9 
hsa‐miR‐671‐5p 0.004974 2.31 1     
hsa‐miR‐1285 0.005449 2.27 1     
hsa‐miR‐1909STAR 0.006209 2.76 1 mir‐1909 19 
hsa‐miR‐1299 0.006331 2.77 1 mir‐1299 9 
hsa‐miR‐623 0.006572 3.06 1 mir‐623 13 
hsa‐miR‐659 0.006688 3.15 1   22 
hsa‐miR‐630 0.007126 2.46 1 mir‐630 15 
hsa‐miR‐202 0.007961 2.93 1 mir‐202 10 
hsa‐miR‐1914STAR 0.008357 1.89 1 mir‐1914 20 
hsa‐miR‐1228STAR 0.008409 2.44 1 mir‐1228 12 
hsa‐miR‐1300 0.009179 2.05 1     
hsa‐miR‐30b 0.009904 0.69 0 mir‐30 8 
hsa‐miR‐149STAR 0.01032 3.18 1 mir‐149 2 
hsa‐miR‐134 0.010548 2.15 1 mir‐134 14 
hsa‐miR‐150STAR 0.010692 2.01 1 mir‐150 19 
hsa‐miR‐493 0.011046 2.59 1 mir‐493 14 
hsa‐miR‐564 0.011733 2.06 1 mir‐564 3 
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SystematicName pmiRNA A 
vs BC 
FC 
A/BC
Cluster Fam Chr 
hsa‐miR‐557 0.01176 2.59 1 mir‐557 1 
hsa‐miR‐663 0.012174 2.09 1 mir‐663 20 
hsa‐miR‐720 0.013643 0.66 0 mir‐720 3 
hsa‐miR‐575 0.0137 2.35 1 mir‐575 4 
hsa‐miR‐610 0.013852 2.86 1 mir‐610 11 
hsa‐miR‐1275 0.014581 1.73 1 mir‐1275 6 
hsa‐miR‐371‐5p 0.015369 2.28 1     
hsa‐miR‐1826 0.015649 1.73 0   16 
hsa‐miR‐183STAR 0.018183 1.56 0 mir‐183 7 
hsa‐miR‐370 0.018404 2.48 1 mir‐370 14 
ebv‐miR‐BART16 0.018733 2.11 0     
hsa‐miR‐1246 0.019089 2.39 0 mir‐1246 2 
hiv1‐miR‐H1 0.019205 2.04 1     
hsa‐miR‐760 0.01971 2.67 1 mir‐760 1 
hsa‐miR‐664STAR 0.022419 1.83 1 mir‐664 1 
hsa‐miR‐1305 0.023204 1.80 1 mir‐1305 4 
hsa‐miR‐26a 0.023411 0.75 0     
hsa‐miR‐198 0.02588 2.35 1 mir‐198 3 
hsa‐miR‐1268 0.030025 1.84 1 mir‐1268 15 
hsa‐miR‐103 0.031032 0.80 0     
hsa‐miR‐1260 0.031227 0.63 0 mir‐1260 14 
hsa‐miR‐135aSTAR 0.031383 2.80 1     
hsa‐miR‐584 0.032723 2.34 1 mir‐584 5 
hsa‐miR‐212 0.034728 1.74 1 mir‐132 17 
hsa‐miR‐494 0.035024 1.71 0 mir‐154 14 
hsa‐miR‐1288 0.036946 2.05 0 mir‐1288 17 
hsa‐miR‐339‐3p 0.038988 1.65 0     
ebv‐miR‐BART13 0.041695 1.80 1     
hsa‐miR‐1202 0.042337 1.84 1 mir‐1202 6 
hsa‐miR‐34aSTAR 0.04236 1.78 0 mir‐34 1 
hsa‐miR‐566 0.044094 2.53 1 mir‐566 3 
hsa‐miR‐572 0.049083 2.68 1 mir‐572 4 
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Fluorescence levels of 66 selected miRNA have been correlated in all 
patients. 
 
Correlation Matrix between miRNA 
 
 
 
           R di Pearson                      Correlation example between 2 miRNA 
 
 
  > 0.9 
  > 0.75 
  > 0.5 
  > 0.25 
  > ‐0.25 
  > ‐0.5 
  > ‐0.75 
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With the aim to obtain a miRNA list, which discriminates Group A patients,  
to validate in RT-PCR, to 66 miRNA list have been applied further filters 
calculated by 4 criteria obtained with Microsoft Excel and 2 criteria with the 
script of “R”, with or without Background subtraction: 
Criterion 1: Probe Validation p <0.1 A s BC 
Criterion 2: miRNA Validation p< 0.15 A vs BC  
Criterion 3: All Dataset  miRNA pvalue < 0.05  (used to obtain  first 
selection of miRNA) 
Criterion 4: All Dataset  miRNA qvalue <0.15  
Criterion 5: R without subtraction of BG q value <0.1 
Criterion 6: R with subtraction of BG q value <0.1  
 
2.4 Results 
We have been able to identify 14 miRNA which are specific for Group A 
(TRG 1) with respect of other groups (B,C). These miRNAs have 
fluorescence levels higher in Group A than B and C; moreover, they have a 
fluorescence value which changes in the same way in patients of these 
group, namely they are strongly linked each other and form a “cluster”. This 
cluster correlate with TRG1 with a specificity of 83% and sensitivity of 
78%. The cluster may be an interesting marker: all miRNA in the cluster are 
overexpressed together in the same patients of group A (fig.6).   
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Fig. 6: List of 14 selected miRNA specific for Group A 
SystematicName R p A 
vs BC 
R p B 
vs C 
R p 
AB vs 
C 
Amedia
FC 
A/BC
FC AB/C
Clust
er Famaccession Chr Chr coord 
Chr 
coord 
hsa‐miR‐765 0.00040.67980.51865.1333 2.87861.6013 1 mir‐
765
MI00051161 15690592
3 
15690603
6 
hsa‐miR‐1183 0.00070.79480.45155.6190 3.02361.5772 1 mir‐
1183
MI00062767 21510676 21510764
hsv1‐miR‐H1 0.00090.57620.85525.1133 3.44001.3587 1           
hsa‐miR‐1274b 0.00200.23070.261310.7036 0.69770.7538 0 mir‐
1274
MI000642719 58024375 58024441
hsa‐miR‐483‐5p 0.00200.79970.43086.6362 2.42621.4091 1           
hsa‐miR‐622 0.00210.74060.60135.3691 2.97241.6474 1 mir‐
622
MI000363613 90883436 90883531
hsa‐miR‐125a‐3p 0.00220.85380.69418.1461 2.35531.4111 1           
hsa‐miR‐1224‐5p 0.00260.94320.53876.2904 2.31171.2981 1           
hsa‐miR‐188‐5p 0.00300.90480.54916.1835 2.29781.2825 1           
hsa‐miR‐1471 0.00350.81540.57035.0645 3.11981.4947 1 mir‐
1471
MI00070762 23275695
2 
23275700
8 
hsa‐miR‐671‐5p 0.00500.79510.56866.0724 2.30971.1934 1           
hsa‐miR‐1909STAR 0.00620.68700.74195.0301 2.76381.2836 1 mir‐
1909
MI000833019 1816158 1816237 
hsa‐miR‐630 0.00710.38570.87536.0162 2.46321.0758 1 mir‐
630
MI000364415 72879558 72879654
hsa‐miR‐720 0.01360.30930.308210.3321 0.66120.7368 0 mir‐
720
MI00066543 16405912
9 
16405923
8 
 
This miRNA profile may be proposed as a specific “signature” to validate in 
RT-PCR. 
  A A A A A A A A A B B B B B B B B B B B B B B B B B B B B C C C C C C C C C C
  8 9 23 25 26 40 41 43 46 2 3 4 5 6 10 11 14 16 17 18 29 30 31 32 44 47 48 49 50 1 7 12 13 24 27 28 38 42 45
hsa‐miR‐
1183                                                                              
hsa‐miR‐
1224‐5p                                                                              
hsa‐miR‐
125a‐3p                                                                              
hsa‐miR‐
1471                                                                              
hsa‐miR‐
188‐5p                                                                              
hsa‐miR‐
1909STAR                                                                              
hsa‐miR‐
483‐5p                                                                              
hsa‐miR‐
622                                                                              
hsa‐miR‐
630                                                                              
hsa‐miR‐
671‐5p                                                                              
hsa‐miR‐
765                                                                              
hsv1‐miR‐
H1                                                                              
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Out of 
cluster  
                                                                            
hsa‐miR‐
1274b                                                                              
hsa‐miR‐
720                                                                              
 
Validation of the microarray results by real-time qPCR 
To detect the expression level of miRNA by real-time qPCR, TaqMan® 
microRNA assay (Applied Biosystems) was used to quantify the relative 
expression levels of 14 miRNA identified (see fig. 5). cDNA was 
synthesized by Taqman miRNA RT Kit (Applied Biosystems). Total RNA 
(10 ng) in 5 ul of nuclease free water was added to 3 ul of 5× RT primer, 
10× 1.5 ul of reverse transcriptase buffer, 0.15 ul of 100 mM dNTP, 0.19 ul 
of RNase inhibitor, 4.16 ul of nuclease free water, and 50 U of reverse 
transcriptase in a total volume of 15 ul. The reaction was performed for 30 
min at 16°C, 30 min at 42°C, and five min at 85°C. All RT reactions were 
run in triplicate. Chromo 4 detector (BIO-RAD, Hercules, CA, USA) was 
used to detect miRNA expression. 
 
2.5 Discussion 
MicroRNAs are small RNAs that regulate gene expression at the post-
transcriptional level. miRNAs exert an important role in the regulation of 
biological processes, and abnormal expression of miRNAs are associated 
with different cancers. Considering the strong association between genetic 
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alterations and neoplastic diseases, it is not surprising that there is a special 
focus on the correlation between miRNAs and cancer. Several  experimental 
studies on colorectal cancer, the most common cancer site and furthermore 
the second most common cause of death due to cancer, have highlighted the 
critical role of miRNA in regulation of wellknown oncogenic and tumour 
suppressor signalling pathways. 
Furthermore, several investigations have described the ability of microRNA 
expression patterns to predict prognosis in colon cancer and support 
diagnosis of poorly differentiated tumours. Currently, two different 
approaches are applied to investigate the association between miRNA and 
colorectal cancer (CRC). On the one hand, miRNAs seem to regulate many 
known oncogenic and tumour suppressor pathways involved in the 
pathogenesis of CRC. This is of particular interest in colorectal neoplasms 
as many proteins involved in key signalling pathways in this tumour, like 
p53, RAS and epithelial–mesenchymal transition (EMT) transcription 
factors as well as members of the PI-3-K and the Wnt/β-catenin pathway 
seem to be affected by miRNA regulation. Their dissection in functional 
studies is critical for a better understanding of cancer biology, eventually 
aiming for the identification of novel pharmaceutical targets. On the other 
hand, expression profiles of hundreds of different miRNAs have been 
shown to bear a much higher potential as biomarkers than their mRNA 
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counterparts. This allows a prediction of prognosis and a distinction of 
certain disease entities including colorectal cancer sub-types. 
In order to investigate miRNA differential expression in human colorectal 
cancer, we analyzed by microarray and real-time PCR the expression of 939 
mature miRNAs in total RNA extracted from 39 rectal fresh frozen biopsies, 
with the aim to found a “signature” that correlates with the response to 
treatments.   
Total RNA was extracted from biopsies of patients affected by a locally 
advanced rectal cancer, treated with neo-adjuant chemo-radiotherapy, 
follwing by surgery. RNA concentration was tested by Nanodrop  ND 1000 
spectrophotometer (fig 7) and  by Agilent Bioanalyzer Assay to measure the 
total RNA integrity (RIN) and concentration (fig. 8). Also small RNA was 
tested by Small RNA Kit to characterize the fraction of miRNAs (fig. 9). 
The expression level of mature miRNAs found their biopsy specimen, 
obtained prior to the combination therapy, were quantified using microarray 
analysis (fig. 10). The miRNA expression pattern was classified based on 
the final pathological response to the combination therapy. 
We found that the expression level of 14 miRNAs were significantly 
different in patients with TRG 1 if compared with patients with other TRG, 
with a sensitivity of 78% and a specificity of 80%. The miRNA expression 
pattern is associated with therapeutic outcome and may be a specific 
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“signature”. This information could be utilized as a novel biomarker to 
predict drug response. 
 Fig. 7: Nanodrop Spectrophotometer evaluation 
 
 
 
         Fig. 8: Total RNA Integrity Number (RIN) 
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Fig. 9: Small RNA (miRNAs fraction 40-50 nt) 
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Fig. 10 
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